Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | MGLL | Q99685 | 3/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | PHGDH | O43175 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13158203 | 1.00 | POLB (0.55) | POLBALDH1A1MGLLHSD17B10PHGDH | |
| SCHEMBL13157795 | 1.00 | POLB (0.55) | POLBALDH1A1MGLLHSD17B10PHGDH | |
| SCHEMBL3100943 | 0.94 | GPR183 (0.56) | POLBALDH1A1MGLLHSD17B10PHGDH | |
| SCHEMBL13157727 | 0.94 | GPR183 (0.56) | POLBALDH1A1MGLLHSD17B10PHGDH | |
| SCHEMBL13157702 | 0.94 | GPR183 (0.56) | POLBALDH1A1MGLLHSD17B10PHGDH | |
| SCHEMBL3102439 | 0.94 | HSP90AA1 (0.59) | POLBALDH1A1MGLLKMT2ASLC18A3 | |
| SCHEMBL3098390 | 0.94 | GPR183 (0.56) | POLBALDH1A1MGLLHSD17B10PHGDH | |
| SCHEMBL13157715 | 0.94 | HSP90AA1 (0.59) | POLBALDH1A1MGLLKMT2ASLC18A3 | |
| SCHEMBL13182498 | 0.93 | POLB (0.51) | POLBALDH1A1MGLLHSD17B10PHGDH | |
| SCHEMBL3107805 | 0.93 | SLC18A3 (0.48) | POLBALDH1A1MGLLHSD17B10PHGDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399455-B2 | Compounds useful as chemokine receptor antagonists | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20100234356-A1 | COMPOUNDS USEFUL AS CHEMOKINE RECEPTOR ANTAGONISTS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-7635698-B2 | Compounds useful as chemokine receptor antagonists | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-20060189628-A1 | Compounds useful as chemokine receptor antagonists | MILLENNIUM PHARMACEUTICALS, INC. | 2006-08-24 | — | — | US | disclosed |
| WO-2006071958-A1 | COMPOUNDS USEFUL AS CHEMOKINE RECEPTOR ANTAGONISTS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234356-A1 | COMPOUNDS USEFUL AS CHEMOKINE RECEPTOR ANTAGONISTS | ACKR3, CCR5, CXCR2 | POLB 3618/4885ALDH1A1 1889/4885MGLL 2345/4885 |
| US-20060189628-A1 | Compounds useful as chemokine receptor antagonists | ACKR3, CCR5, CXCR2 | POLB 3618/4885ALDH1A1 1889/4885MGLL 2345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.